VivoSim Labs, Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 21 Aug 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 24 Jul 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Annual report filed late (NT 10-K)
The company filed Form NT 10-K with the SEC on 29 Jun 2026, notifying investors that its annual report would be late. A late annual report can point to accounting or audit problems, though the reason is sometimes routine.
More details →VivoSim Labs, Inc. — Overview & Financial Snapshot
VivoSim Labs, Inc. (NasdaqCM: VIVS) is a Healthcare company, ranked #6,427 of 6,774 companies globally and #3,690 of 4,000 in United States on PositoAI, with a Positivity Score of -19,298. Its market capitalisation is ₹24.96 Cr ($2.64M), P/E ratio is -0.0 and P/B ratio is -1.13. It currently has 2 active red flags (PosiRed) and 1 yellow flag (PosiYellow, 4/10 points) on record.
For financial statements, ratio trends and score history, Go Deep →